- Clinical Trials
- January 2024
- 60 Pages
Global
From €1426EUR$1,500USD£1,198GBP
- Drug Pipelines
- January 2023
- 30 Pages
United States
From €2614EUR$2,750USD£2,196GBP
- Report
- January 2022
- 200 Pages
Global
From €7130EUR$7,500USD£5,990GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- February 2024
- 180 Pages
Global
From €4724EUR$4,969USD£3,968GBP
- Report
- February 2024
- 115 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- August 2022
- 106 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- January 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,314GBP
- Report
- January 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,314GBP
- Report
- October 2023
- 145 Pages
Global
From €2995EUR$3,150USD£2,516GBP
- Report
- August 2022
- 117 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- November 2023
- 147 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- October 2023
- 178 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- May 2018
- 127 Pages
Global
From €14255EUR$14,995USD£11,976GBP
- Report
- September 2023
- 122 Pages
North America
From €1426EUR$1,500USD£1,198GBP
- Drug Pipelines
- July 2023
- 139 Pages
Global
From €14255EUR$14,995USD£11,976GBP
- Report
- January 2024
- 26 Pages
Global
€16304EUR$17,150USD£13,697GBP

Dyskinesia is a neurological disorder characterized by involuntary, repetitive movements. It is most commonly associated with the use of certain central nervous system drugs, such as antipsychotics and levodopa. Dyskinesia can cause a range of physical symptoms, including jerky movements, tremors, and difficulty with coordination. It can also lead to psychological symptoms, such as anxiety and depression.
The dyskinesia market is composed of a range of pharmaceutical companies that produce drugs to treat the disorder. These companies develop and market medications that can reduce the severity of symptoms and improve quality of life. Many of these drugs are approved by the FDA and are available in both generic and brand-name forms.
Some of the companies in the dyskinesia market include AbbVie, Allergan, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Teva Pharmaceuticals. Show Less Read more